Latest & greatest articles for dabigatran

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dabigatran or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dabigatran and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dabigatran

81. [Dabigatran to prevent stroke in patients with atrial fibrillation]

[Dabigatran to prevent stroke in patients with atrial fibrillation] Dabigatran för att förebygga stroke vid förmaksflimmer [Dabigatran to prevent stroke in patients with atrial fibrillation] Dabigatran för att förebygga stroke vid förmaksflimmer [Dabigatran to prevent stroke in patients with atrial fibrillation] SBU Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation SBU. Dabigatran för att förebygga stroke vid förmaksflimmer. [Dabigatran to prevent stroke in patients with atrial fibrillation] Stockholm: The Swedish Council on Health Technology Assessment (SBU). SBU Alert 2011-04. 2011 Final publication URL Additional data URL Indexing Status Subject indexing assigned by CRD MeSH Atrial Fibrillations; Benzimidazoles; Pyridines; Stroke Language Published Swedish Country of organisation Sweden English summary An English language summary

Health Technology Assessment (HTA) Database.2011

82. [Dabigatran etexilate for the prevention of stroke or systemic embolism in patients with non-vascular atrial fibrillation]

[Dabigatran etexilate for the prevention of stroke or systemic embolism in patients with non-vascular atrial fibrillation] Dabigatran etexilat en la profilaxi de l'accident vascular cerebral i de l'embolisme sistèmic en fibril·lació auricular no valvular [Dabigatran etexilate for the prevention of stroke or systemic embolism in patients with non-vascular atrial fibrillation] Dabigatran etexilat en la profilaxi de l'accident vascular cerebral i de l'embolisme sistèmic en fibril·lació auricular (...) no valvular [Dabigatran etexilate for the prevention of stroke or systemic embolism in patients with non-vascular atrial fibrillation] Gómez D, Paladio N, Almazán C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Gómez D, Paladio N, Almazán C. Dabigatran etexilat en la profilaxi de l'accident vascular cerebral i de l'embolisme sistèmic en

Health Technology Assessment (HTA) Database.2011

83. The Efficacy of Dabigatran versus Warfarin for Stroke Prevention in Patients With Atrial Fibrillation: Systematic Review

The Efficacy of Dabigatran versus Warfarin for Stroke Prevention in Patients With Atrial Fibrillation: Systematic Review "The Efficacy of Dabigatran versus Warfarin for Stroke Prevention in Pa" by Karim Bouferrache < > > > > > Title Author Date of Award 4-20-2011 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Patients with atrial fibrillation are at increased risk of experiencing embolic events. Anticoagulation therapy (...) is known to reduce these events. Warfarin, the only oral anticoagulant available, gives inconsistent results, and thus requires frequent laboratory monitoring and adjustment. A newly FDA approved fixed-dosage direct thrombin inhibitor, dabigatran, has shown some promising results in efficacy and safety. Method: An extensive review of the literature search was performed using the following database: Web of Science, MEDLINE and CINHAL. Two studies met the inclusion and exclusion criteria and were

Pacific University EBM Capstone Project2011

84. Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation.

Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. BACKGROUND: Warfarin reduces the risk for ischemic stroke in patients with atrial fibrillation (AF) but increases the risk for hemorrhage. Dabigatran is a fixed-dose, oral direct thrombin inhibitor with similar or reduced rates of ischemic stroke and intracranial hemorrhage in patients with AF compared with those of warfarin. OBJECTIVE: To estimate the quality-adjusted survival, costs, and cost (...) -effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF. DESIGN: Markov decision model. DATA SOURCES: The RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial and other published studies of anticoagulation. The cost of dabigatran was estimated on the basis of pricing in the United Kingdom. TARGET POPULATION: Patients aged 65 years or older with nonvalvular AF and risk factors for stroke (CHADS

Annals of Internal Medicine2010

85. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate

Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM CRD summary The review used indirect evidence (...) to conclude that in patients with atrial fibrillation, dabigatran etexilate significantly reduced the risk of stroke, systemic embolism and mortality compared to placebo, reduced stroke compared to aspirin and reduced stroke and systemic embolism compared to aspirin plus clopidogrel. Study heterogeneity and sensitivity analyses implied that the authors’ conclusions should be treated with caution. Authors' objectives To compare the safety and efficacy of dabigatran etexilate to other treatments for stroke

DARE.2010

86. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged (...) compared oral dabigatran etexilate with subcutaneous enoxaparin, for patients undergoing total knee or hip replacement, who were over 75 years old or had moderate renal impairment. The authors concluded that dabigatran etexilate was superior to enoxaparin because it produced cost savings, with comparable efficacy and safety. The reporting was variable, but the analysis tends to support the authors' conclusions, based on the evidence available. Type of economic evaluation Cost-effectiveness analysis

NHS Economic Evaluation Database.2010

87. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. 20801496 2010 09 20 2010 09 30 2016 06 22 1474-547X 376 9745 2010 Sep 18 Lancet (London, England) Lancet Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial (...) . 975-83 10.1016/S0140-6736(10)61194-4 Effectiveness and safety of warfarin is associated with the time in therapeutic range (TTR) with an international normalised ratio (INR) of 2·0-3·0. In the Randomised Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, dabigatran versus warfarin reduced both stroke and haemorrhage. We aimed to investigate the primary and secondary outcomes of the RE-LY trial in relation to each centre's mean TTR (cTTR) in the warfarin population. In the RE-LY trial

Lancet2010

88. Oral Dabigatran Etexilate: an Emerging Alternative to Conventional Anticoagulation Therapy

Oral Dabigatran Etexilate: an Emerging Alternative to Conventional Anticoagulation Therapy "Oral Dabigatran Etexilate: an Emerging Alternative to Conventional Ant" by Megan C. Merritt < > > > > > Title Author Date of Award 8-14-2010 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor James Ferguson PA-C, MPH Second Advisor Annjanette Sommers MS, PAC Third Advisor Rob Rosenow PharmD, OD Rights . Abstract Background: Thromboembolic events (...) of anticoagulation both for patients and prescribers, and would likely increase adherence to prophylactic guidelines. Dabigatran etexilate, an oral direct thrombin inhibitor, is poised to offer this advantage, and has been appraised in several diverse settings of thromboembolic risk. While authorized for use in Europe, it awaits FDA approval in the United States. Methods: An exhaustive search of available medical literature was performed on five databases: MEDLINE, CINAHL, ISI World of Science, the National

Pacific University EBM Capstone Project2010

90. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting

A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium (...) , dabigatran etexilate, and enoxaparin sodium, for the primary prevention of venous thromboembolism in patients undergoing elective total hip or knee replacement. Rivaroxaban was less costly and more effective than dabigatran and enoxaparin, following either hip or knee replacement, but the probabilistic analysis showed uncertainty in rivaroxaban being more cost-effective than dabigatran etexilate, when both were compared with enoxaparin. Methodologically, the study was well conducted and the authors

NHS Economic Evaluation Database.2009

91. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery Wolowacz S E, Roskell N S, Maciver F, Beard S M, Robinson P A, Plumb J M, Dolan G, Brenkel I J (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of oral dabigatran etexilate (DE) versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement

NHS Economic Evaluation Database.2009

92. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety

Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative (...) clinical-effectiveness and safety Ndegwa S, Moulton K, Argaez C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ndegwa S, Moulton K, Argaez C. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety . Ottawa: Canadian Agency

Health Technology Assessment (HTA) Database.2009

93. Dabigatran versus warfarin in patients with atrial fibrillation.

Dabigatran versus warfarin in patients with atrial fibrillation. 19717844 2009 09 17 2009 09 23 2015 11 19 1533-4406 361 12 2009 Sep 17 The New England journal of medicine N. Engl. J. Med. Dabigatran versus warfarin in patients with atrial fibrillation. 1139-51 10.1056/NEJMoa0905561 Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. In this noninferiority trial (...) , we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, adjusted-dose warfarin. The median duration of the follow-up period was 2.0 years. The primary outcome was stroke or systemic embolism. Rates of the primary outcome were 1.69% per year in the warfarin group, as compared with 1.53% per year in the group that received 110 mg of dabigatran

NEJM2009

94. Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Dabigatran versus warfarin in the treatment of acute venous thromboembolism. 19966341 2009 12 16 2010 01 05 2015 11 19 1533-4406 361 24 2009 Dec 10 The New England journal of medicine N. Engl. J. Med. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. 2342-52 10.1056/NEJMoa0906598 The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism (...) . In a randomized, double-blind, noninferiority trial involving patients with acute venous thromboembolism who were initially given parenteral anticoagulation therapy for a median of 9 days (interquartile range, 8 to 11), we compared oral dabigatran, administered at a dose of 150 mg twice daily, with warfarin that was dose-adjusted to achieve an international normalized ratio of 2.0 to 3.0. The primary outcome was the 6-month incidence of recurrent symptomatic, objectively confirmed venous thromboembolism

NEJM2009

95. Rivaroxaban and dabigatran for thromboprophylaxis in patients undergoing total hip or knee replacement

Rivaroxaban and dabigatran for thromboprophylaxis in patients undergoing total hip or knee replacement Home - Monash Health Find a Location Latest news We are delighted to begin construction on the Victorian Heart Hospital, Australia’s first dedicated state-of-the art cardiac facility. Your health Protect your health and safety while you travel this holiday season by planning ahead and preparing for the unexpected. Our children’s hospital Monash Children’s Hospital is one of Australia’s leading

Monash Health Evidence Reviews2009

96. Dabigatran Etexilate - Primary prevention of venous thromboembolic events in adult patients who have undergone total hip replacement surgery or total knee replacement surgery

Dabigatran Etexilate - Primary prevention of venous thromboembolic events in adult patients who have undergone total hip replacement surgery or total knee replacement surgery

Scottish Medicines Consortium2008

97. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157)

Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157) Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults | Guidance and guidelines | NICE Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults Technology appraisal guidance [TA157] Published date: 24 September 2008 Share Guidance wherever possible. Explore

National Institute for Health and Clinical Excellence - Technology Appraisals2008

98. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. 17869635 2007 09 17 2007 09 28 2015 11 19 1474-547X 370 9591 2007 Sep 15 Lancet (London, England) Lancet Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. 949-56 After hip replacement surgery, prophylaxis following discharge from (...) hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis. In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after surgery, or subcutaneous enoxaparin 40 mg once daily (1162), starting the evening before surgery. The primary

Lancet2007

99. Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing

Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing NHSC Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2006 Authors' objectives This study examines the use of dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery. Timeliness warning Available on request from NHSC. Final

Health Technology Assessment (HTA) Database.2006